ELMMB logo
Facebook logo Twitter logo
NICE Highly Specialised Technology Guidance

NICE Highly Specialised Technology Guidance

Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.
 Date  Highly Specialised Technology Guidance
 January 2015  HST1 - Eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome
 December 2015  HST2 Elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa
 July 2016  HST3 - Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
 February 2017  HST4 Migalastat (Galafold) for treating Fabry disease
 June 2017  HST5 - Eliglustat (Cerdelga) for treating type 1 Gaucher disease 
 August 2017  HST6 - Asfotase (Strensiq) alfa for treating paediatric-onset hypophosphatasia
 February 2018  HST7 - Strimvelis for treating adenosine deaminase deficiency-severe combined immunodeficiency
 October 2018  HST8 - Burosumab (Crysvita) for treating X-linked hypophosphataemia in children and young people 
 May 2019  HST9 - Inotersen (Tegsedi) for treating hereditary transthyretin amyloidosis
 August 2019  HST10 - Patisiran (Onpattro) for treating hereditary transthyretin amyloidosis 
 November 2019  HST11 - Voretigene neparvovec (Luxturna) - for treating inherited retinal dystrophies caused by RPE65 gene mutations
 December 2019  HST12 - Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2
 All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the
 public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service 
 Email: info.elmmb@nhs.net
 Copyright© 2019 East Lancashire Medicines Management Board 
 All rights reserved.  Disclaimer/Terms and conditions